Cancer News and Research

Latest Cancer News and Research

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

19 Aug 2009

News outlets continue to explain how end-of-life care counseling works

NPR talks with Dr. David Casarett, associate professor of medicine at the University of Pennsylvania who started the palliative care service at the VA hospital in Philadelphia, about "the rhetoric around the end-of-life issues addressed in some of the proposed health care legislation" (Block, 8/18).

19 Aug 2009

New tool for scientists - light used to manipulate cell movement

One of the biggest challenges in scientists' quest to develop new and better treatments for cancer is gaining a better understanding of how and why cancer spreads. Recent breakthroughs have uncovered how different cellular proteins are turned 'on' or 'off' at the molecular level, but much remains to be understood about how protein signaling influences cell behavior.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.

19 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

New "micropatterning" method useful in gene expression studies

Like oil and water, two water-based liquids can mingle without mixing in a new University of Michigan technology developed for biological experiments.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

BioDelivery Sciences International, Inc. (BDSI®) (Nasdaq:BDSI) today announced that it has retained ICR, a leading investor relations and strategic advisory firm, to assist in the Company's shareholder communications program. ICR, founded in 1998 by a group of former institutional capital markets professionals, is headquartered in Westport, Connecticut, with offices in Westport, New York, Los Angeles, Boston, Chicago, Minneapolis, Beijing, and Shanghai.

19 Aug 2009

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Forty-six uninsured San Diego County patients will receive donated outpatient surgeries and procedures on Saturday, August 22, 2009, through an ongoing partnership between Project Access San Diego (PASD), a program of the San Diego County Medical Society Foundation, Kaiser Permanente and the Alliance Healthcare Foundation. PASD mobilizes medical volunteers to provide free surgeries and procedures to uninsured San Diegans.

19 Aug 2009

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

A study published in the Proceedings of the National Academy of Sciences (PNAS) shows that the virus blocks the actions of a specific ion channel in the cell membrane that would usually trigger apoptosis - the cell's self-destruct programme - and in doing so, has evolved another way of protecting itself from being eliminated from the body.

19 Aug 2009

Arzoxifene phase 3 study results reported by Lilly

Eli Lilly and Company announced today that initial results from its pivotal, five-year, Phase III GJAD "GENERATIONS" trial for arzoxifene met its primary endpoints of significantly reducing the risk of vertebral fracture and invasive breast cancer in postmenopausal women.

19 Aug 2009

BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.

19 Aug 2009

Hospital Corporation of America appoints Bayard Advertising Agency as recruitment partner

Bayard Advertising Agency, Inc., an integrated branding and communications agency serving B2B and B2C clients in a broad array of industries, announces its selection as Recruitment Agency Of Record by Hospital Corporation of America (HCA) West Florida Division.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

Women air concerns on government takeover of health care

300,000 American women with breast cancer might have died over the last decade, if the US had adopted a British-style, government-run health care system. This shocking figure, from recent studies by the Lewin Group and Lancet Oncology, appears in a TV ad launched today by The Independent Women's Forum, a non-profit organization focused on issues of concern for women. The 60-second spot highlights the deadly risks to women under the "public option" - or co-op - plan currently under consideration in Congress.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Patients who experience fatigue during radiotherapy for breast or prostate cancer may be reacting to activation of the proinflammatory cytokine network, a known inflammatory pathway, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

19 Aug 2009

Cancer News and Research

Latest Cancer News and Research

Nano-bio material kills cancer cells, leaves healthy cells in unharmed

News outlets continue to explain how end-of-life care counseling works

New tool for scientists - light used to manipulate cell movement

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Light Sciences Oncology announces Phase 2 trial of Aptocine in Benign Prostatic Hyperplasia

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

ImmunoCellular Therapeutics to participate in the Southern California Investor Conference

CEL-SCI expands work on current H1N1 virus vaccine

New "micropatterning" method useful in gene expression studies

Light-activated delivery system enhances anti-tumour drug potency

BioDelivery Sciences International utilizes ICR's services for shareholder communications program

Forty-six uninsured San Diego County patients to receive free surgeries, procedures

Discovery of mechanism that allows hepatitis C virus to remain in the body for decades

Arzoxifene phase 3 study results reported by Lilly

BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA

Hospital Corporation of America appoints Bayard Advertising Agency as recruitment partner

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

Women air concerns on government takeover of health care

New production technology to develop vaccine for norovirus

Fatigue during radiotherapy for breast or prostate cancer may be caused by inflammation

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in